Clinical Actions of l-Deprenyl in Parkinson’s Disease
Over the past decade a number of investigators have reported on the usefulness of l-deprenyl, a selective inhibitor of monoamine oxidase type B (MAO-B) in the treatment of Parkinson’s disease. To a considerable extent these reports relate to its use as an adjunctive agent to levodopa administered when the therapeutic efficacy of the latter begins to diminish. More recently it has been suggested on theoretical grounds and in limited clinical experience that l-deprenyl may have a more valuable effect in being able to halt or retard the inexorable progressive nature of the underlying disease process of Parkinson’s disease. In this chapter, the clinical experience to date of the use of l-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.
KeywordsMonoamine Oxidase Adjunctive Agent Monoamine Oxidase Type Parkinsonian State Brain Monoamine Oxidase
Unable to display preview. Download preview PDF.
- Barbeau A, Duchastel Y (1962) Tranylcypromine and the extrapyramidal syndrome. Can J Psychiatry 7: 91–95Google Scholar
- Bergmann KJ, Mendoza MR, Yahr MD (1986) Parkinson’s disease and long term levodopa therapy. In: Yahr MD, Bergmann K (eds) Advances in neurology, vol 45. Raven, New York p 463Google Scholar
- Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 19: 89–103Google Scholar
- Ehringer H, Horneykiewicz O (1960) Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 72: 1236Google Scholar
- Goldstein L (1980) The “on-off” phenomena in Parkinson’s disease. Treatment and theoretical considerations. Mt Sinai J Med NY 47: 80–84Google Scholar
- Knoll J, Vizi ES, Somogyi G (1968) Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelforschung 18: 109Google Scholar
- McDowell FH, Sweet RD (1976) The on-off phenomenon. In: Birkmayer W, Horneykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 603–612Google Scholar
- Murphy DL, Wright C, Buchsbaum M et al. (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med Metab Biol 16: 254–265Google Scholar
- Yahr MD (1976) Evaluation of long term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Horneykiewicz O (eds) Advances in parkinsonism. Roche, Basel pp 435–444Google Scholar
- Yahr MD (1984) Limitations of long term use of antiparkinson drugs. Can J Neurol Sci 2: 191–194Google Scholar